All Photos(1)

Documents

1006506

USP

Acetohydroxamic acid

Name: Acetohydroxamic acid
Brand: USP

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

AHA

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Linear Formula:

CH₃CONHOH

CAS Number:

546-88-3

Molecular Weight:

75.07

Beilstein:

1739019

MDL number:

MFCD00009994

UNSPSC Code:

41116107

PubChem Substance ID:

329748882

NACRES:

NA.24

grade

pharmaceutical primary standard

API family

acetohydroxamic acid

manufacturer/tradename

USP

mp

88-90 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CC(NO)=O

InChI

1S/C2H5NO2/c1-2(4)3-5/h5H,1H3,(H,3,4)

InChI key

RRUDCFGSUDOHDG-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Acetohydroxamic acid USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monograph such as Acetohydroxamic Acid Tablets

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Other Notes

Sales restrictions may apply.

Pictograms

GHS08

Signal Word

Danger

Hazard Statements

H360

Precautionary Statements

P201 - P280 - P308 + P313

Hazard Classifications

Repr. 1B

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

New drug therapy for kidney stones: a review of cellulose sodium phosphate, acetohydroxamic acid, and potassium citrate.

K D Lake et al.

Drug intelligence & clinical pharmacy, 19(7-8), 530-539 (1985-07-01)

Kidney stones have an overall incidence of two to three percent in western countries. In many patients, the disease process is difficult to control and recurrence rates are high: 20 to 50 percent over the subsequent ten years. The pathogenesis

Hospital length of stay and clinical outcomes in older STEMI patients after primary PCI: a report from the National Cardiovascular Data Registry.

Rajesh V Swaminathan et al.

Journal of the American College of Cardiology, 65(12), 1161-1171 (2015-03-31)

There has been a decline in hospital length of stay (LOS) after primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI). The objective of this study was to examine whether shorter LOS is safe for older patients undergoing

Perioperative beta blockade in noncardiac surgery: a systematic review for the 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines.

Duminda N Wijeysundera et al.

Journal of the American College of Cardiology, 64(22), 2406-2425 (2014-08-06)

To review the literature systematically to determine whether initiation of beta blockade within 45 days prior to noncardiac surgery reduces 30-day cardiovascular morbidity and mortality rates. PubMed (up to April 2013), Embase (up to April 2013), Cochrane Central Register of

Anthropometric measures in cardiovascular disease prediction: comparison of laboratory-based versus non-laboratory-based model.

Klodian Dhana et al.

Heart (British Cardiac Society), 101(5), 377-383 (2014-12-17)

Body mass index (BMI) has been used to simplify cardiovascular risk prediction models by substituting total cholesterol and high-density lipoprotein cholesterol. In the elderly, the ability of BMI as a predictor of cardiovascular disease (CVD) declines. We aimed to find

Apurinic/apyrimidinic endonuclease 1 upregulation reduces oxidative DNA damage and protects hippocampal neurons from ischemic injury.

Rehana K Leak et al.

Antioxidants & redox signaling, 22(2), 135-148 (2013-11-05)

Apurinic/apyrimidinic endonuclease 1 (APE1) is a multifunctional enzyme that participates in base-excision repair of oxidative DNA damage and in the redox activation of transcription factors. We tested the hypothesis that APE1 upregulation protects neuronal structure and function against transient global

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service